RT info:eu-repo/semantics/article
T1 Predictive modeling of poor outcome in severe COVID-19: A single-center observational study based on clinical, cytokine and laboratory profiles
A1 Gorgojo Galindo, Óscar
A1 Martín Fernández, Marta
A1 Peñarrubia Ponce, María Jesús
A1 Álvarez González, Francisco Javier
A1 Ortega Loubon, Christian Joseph
A1 Gonzalo Benito, Hugo
A1 Martínez de Paz, Pedro José
A1 Miramontes González, José Pablo
A1 Gómez Sánchez, Esther
A1 Poves Álvarez, Rodrigo
A1 Jorge Monjas, Pablo
A1 Tamayo Gómez, Eduardo
A1 Heredia Rodríguez, María
A1 Tamayo Velasco, Álvaro
K1 COVID-19
K1 COVID-19 (Disease) - Diagnosis
K1 Coronaviruses - Diagnosis
K1 Cytokines - Therapeutic use
K1 Biomarkers
K1 2420 Virología
AB Pneumonia is the main cause of hospital admission in COVID-19 patients. We aimed to perform an extensive characterization of clinical, laboratory, and cytokine profiles in order to identify poor outcomes in COVID-19 patients. Methods: A prospective and consecutive study involving 108 COVID-19 patients was conducted between March and April 2020 at Hospital Clínico Universitario de Valladolid (Spain). Plasma samples from each patient were collected after emergency room admission. Forty-five serum cytokines were measured in duplicate, and clinical data were analyzed using SPPS version 25.0. Results: A multivariate predictive model showed high hepatocyte growth factor (HGF) plasma levels as the only cytokine related to intubation or death risk at hospital admission (OR = 7.38, 95%CI—(1.28–42.4), p = 0.025). There were no comorbidities included in the model except for the ABO blood group, in which the O blood group was associated with a 14-fold lower risk of a poor outcome. Other clinical variables were also included in the predictive model. The predictive model was internally validated by the receiver operating characteristic (ROC) curve with an area under the curve (AUC) of 0.94, a sensitivity of 91.7% and a specificity of 95%. The use of a bootstrapping method confirmed these results. Conclusions: A simple, robust, and quick predictive model, based on the ABO blood group, four common laboratory values, and one specific cytokine (HGF), could be used in order to predict poor outcomes in COVID-19 patients.
PB MDPI
SN 2077-0383
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/59095
UL https://uvadoc.uva.es/handle/10324/59095
LA eng
NO Journal of Clinical Medicine, 2021, Vol. 10, Nº. 22, 5431
NO Producción Científica
DS UVaDOC
RD 23-nov-2024